# Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential

> **NCT04680273** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** [14C]-GDC-9545
- **DRUG:** GDC-9545 Solution for Infusion
- **DRUG:** GDC-9545/F12 Capsule
- **DRUG:** GDC-9545/F18 Capsule

## Key facts

- **NCT ID:** NCT04680273
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-07
- **Primary completion:** 2021-04-12
- **Final completion:** 2021-04-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04680273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04680273, "Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04680273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*